Please assess the completion status of the following clinical trial:

Trial Title: A Phase 2/3 Study of TVP-1012 at 0.5 mg or 1 mg in Levodopa Treated Parkinson's Disease Participants

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2/PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* In the opinion of the investigator or sub-investigator, the participant is capable of understanding and complying with protocol requirements.~* The participant signs and dates a written, informed consent form and any required privacy authorization prior to the initiation of any study procedures.~* The participant has a diagnosis of Parkinson's disease according to the diagnostic criteria of the UK Parkinson's Disease Society Brain Bank.~* The participant has Modified Hoehn \& Yahr stage 2 to 4 (in the Off state) at the start of the run-in period.~* The participant has wearing off phenomenon and has been continuously receiving a levodopa combination drug for \>= 6 months prior to the start of the run-in period.~* The participant has been receiving a levodopa combination drug with a stable dose regimen (dosing frequency, at least 3 times a day) since the start of the run-in period.~* For participants receiving eantacapone concomitantly,the participant has been receiving entacapone with a stable dose regimen from the start of the run-in period.~* For participants receiving a dopamine agonist, anticholinergic drug, amantadine, droxidopa, istradefylline, or zonisamide concomitantly, the participant has been receiving those drugs with a stable dose regimen since 14 days prior to the start of the run-in period.~* The participant is an outpatient of either sex aged \>= 30 and \< 80 years at the time of consent.~* A female participant of childbearing potential who is sexually active with a nonsterilized male partner agrees to use routinely adequate contraception from signing of informed consent to 1 month after the last dose of the investigational drug.~* The participant has completed patient diary for at least 4 of the 7 days preceding the study visit at the end of the run-in period.~* The participant has mean daily off-time of \>= 2.5 hours at the end of the run-in period~Exclusion Criteria:~* The participant has received any investigational medication within 90 days prior to the start of the run-in period.~* The participant has received TVP-1012 in the past.~* The participant is a study site employee, an immediate family member, or in a dependent relationship with a study site employee who is involved in the conduct of this study (e.g., spouse, parent, child, sibling) or may consent under duress.~* Participant has donated 400 mL or more of his or her blood volume within 90 days prior to the start of the run-in period.~* The participant has unstable systemic disease.~* The participant has severe dyskinesia.~* The participant has Mini-Mental State Examination (MMSE) score of \<= 24 at the start of the run-in period.~* The participant has known or a history of schizophrenia, major or severe depression, or any other clinically significant psychiatric disease~* The participant has major depression or severe depression, or any other clinically significant psychiatric disease.~* The participant has a history of hypersensitivity or allergies to TVP-1012 (including any associated excipients) or selegiline.~* The participant has a history of clinically significant hypertension or other reactions associated with ingestion of tyramine-rich food (e.g., cheese, lever, herring, yeast, horsebean, banana, beer or wine).~* The participant has a history or concurrent of drug abuse or alcohol dependence.~* The participant has received neurosurgical intervention for Parkinson's disease (e.g., pallidotomy, thalamotomy, deep brain stimulation).~* The participant has received transcranial magnetic stimulation within 6 months prior to the start of the run-in period.~* The participant has received selegiline, pethidine, tramadol, reserpine or methyldopa within 90 days prior to the start of the run-in period.~* The participant has received single agent of levodopa, any psychoneurotic agent or antiemetic medication of dopamine antagonist within 14 days prior to the start of the run-in period. However, the participant has been receiving quetiapine or domperidone with a stable dose regimen for \>= 14 days prior to the start of the run-in period may be included in the study.~* The participant is required to take any of the prohibited concomitant medications or treatments.~* If female, the participant is pregnant or lactating or intending to become pregnant during, or within 1 month after the last administration of study medication in this study; or intending to donate ova during such time period.~* The participant has clinically significant neurologic, cardiovascular, pulmonary, hepatic (including mild cirrhosis), renal, metabolic, gastrointestinal, urological, endocrine, or hematological disease.~* The participant has clinically significant or unstable brain or cardiovascular disease, such as:~  * clinically significant arrhythmia or cardiac valvulopathy,~ * heart failure of NYHA Class II or higher,~ * concurrent or a history of ischemic cardiac disease within 6 months prior to the start of the run-in period,~ * concurrent or a history of clinically significant cerebrovascular disease within 6 months prior to the stat of the run-in period,~ * severe hypertension (systolic blood pressure of 180 mmHg or higher, or diastolic blood pressure of 110 mmHg or higher),~ * clinically significant orthostatic hypotension (including those with diastolic pressure decrease of 30 mmHg or more following postural change from supine/sitting position to standing position), or~ * a history of syncope due to hypotension within 2 years prior to the stat of the run-in period.~* The participant is required surgery or hospitalization for surgery during the study period.~* Participant has a history of cancer within 5 years prior to the start of the run-in period, except cervix carcinoma in situ which has completely cured.~* The participant has acquired immunodeficiency syndrome (AIDS) \[including human immunodeficiency virus (HIV) carrier\], or hepatitis \[including viral hepatitis carrier such as hepatitis B surface (HBs) antigen or hepatitis C antibody (HCV) positive\]. However, the participant who has a negative result for HCV antigen or HCV-RNA can be included in the study.~* The participant has laboratory data meeting any of the following at the start of the run-in period:~  * Creatinine \>= 2 x upper limit of normal (ULN)~ * Total bilirubin \>= 2 x ULN~ * ALT or AST \>= 1.5 x ULN~ * ALP \>= 3 x ULN~* The participant has received any of the prohibited concomitant medications or treatments during the run-in period.~* The participant who, in the opinion of the investigator or sub-investigator, is unsuitable for any other reason.

- Gender: ALL
- Minimum Age: 30 Years
- Maximum Age: 79 Years
- Healthy Volunteers: f

Study Arms:
- TVP-1012 1mg (Type: EXPERIMENTAL): TVP-1012 1 mg once daily orally, before or after breakfast, concomitantly with levodopa tablet for 26 weeks as treatment period after 2 weeks of run-in period.
- TVP-1012 0.5mg (Type: EXPERIMENTAL): TVP-1012 0.5 mg once daily orally, before or after breakfast, concomitantly with levodopa tablet for 26 weeks as treatment period after 2 weeks of run-in period.
- Placebo (Type: PLACEBO_COMPARATOR): One placebo tablet once daily orally, before or after breakfast, concomitantly with levodopa tablet for 26 weeks as treatment period after 2 weeks of run-in period.

Based on this trial design, predict the completion outcome and termination type (if applicable).